Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_01831 |
| Species: | Homo sapiens |
| Position : | chr1:154149500-154150000 |
| Year: | 2024 |
| Title: | A transcriptional enhancer regulates cardiac maturation |
| Genome Build: | hg38 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | Burkitt lymphoma |
| PMID: | 39196225 |
| MONDO: | MONDO:0002483 |
| Tissue: | Blood |
| Tissue Ontology ID: | UBERON:0000178 |
| Cell Source: | Raji |
| CVCL ID: | CVCL_0511 |
| Cell Type: | Burkitt lymphoma cell |
| Cell Ontology ID: | CL:0000945 |
| Experiment Type: | Enhancer activity assay, TF binding assay |
| High Throughput Method: | ChIP-seq, ATAC-seq, RNA-seq |
| Low Throughput Method: | Luciferase Reporter Assay, ChIP-RT-qPCR, CRISPR Knockout, RT-RT-qPCR |
| Target gene : | ACTN2 |
| TF name : | MEF2A |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| MEF2A | CDO in myogenesis | reactome | 29 |
| MEF2A | ERK/MAPK targets | reactome | 17 |
| MEF2A | Signaling mediated by p38-alpha and p38-beta | pid | 35 |
| MEF2A | TGF_beta_Receptor | netpath | 220 |
| MEF2A | Hs_p38_MAPK_Signaling_Pathway_WP400_72084 | wikipathways | 28 |
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_01407 | chr1:154150000-154150500 | Heart | cardiomyocyte | -- |